Merck KGaA to ask EU agency to reconsider MS oral drug
Merck KGaA to ask EU agency to reconsider MS oral drug
German drugmaker Merck KGaA plans to ask a European watchdog to review a negative opinion issued on multiple sclerosis drug cladribine last month that said the drug's risks outweighed its benefits.
"Merck is committed to the potential of cladribine tablets to meet an unmet medical need as an oral, short-course, disease-modifying drug for multiple sclerosis," the group said in a statement on Monday.
The drug was dealt a major blow in September when the Committee for Medicinal Products for Human Use (CHMP), whose view is invariably adopted by the European Commission for approval of decisions, found that the drug may not be fit for approval. [ID:nLDE68N04J]... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1629
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 1 Replies
- 1146 Views
-
Last post by Petr75
-
- 0 Replies
- 161 Views
-
Last post by NHE
-
- 0 Replies
- 1682 Views
-
Last post by NHE
-
- 0 Replies
- 549 Views
-
Last post by NHE
-
- 1 Replies
- 3176 Views
-
Last post by Tif
-
- 0 Replies
- 164 Views
-
Last post by DIM
-
- 2 Replies
- 1108 Views
-
Last post by DIM
-
- 1 Replies
- 2012 Views
-
Last post by raceya